The level of IFN-I-stimulated genes was related to the poor efficacy of ICB in patients of melanoma or breast cancer, and anti-IFNAR-1 antibody overcame the drug resistance of anti-PD1 antibody in mouse liver cancer (82). This evidence concerns the gene IFNAR1 and liver cancer.